PMID- 35247625 OWN - NLM STAT- MEDLINE DCOM- 20220614 LR - 20220728 IS - 2210-741X (Electronic) IS - 2210-7401 (Linking) VI - 46 IP - 5 DP - 2022 May TI - Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis. PG - 101893 LID - S2210-7401(22)00036-5 [pii] LID - 10.1016/j.clinre.2022.101893 [doi] AB - PURPOSE: To evaluate clinical outcomes of drug-eluting beads transarterial chemoembolization (DEB-TACE) with CalliSpheres microspheres and conventional TACE (cTACE) as the initial treatment in patients with unresectable hepatocellular carcinoma (HCC) beyond up-to-seven criteria. METHODS: The study retrospectively assessed the medical records of HCC patients beyond up-to-seven criteria who received the initial treatment of DEB-TACE or cTACE from June 2016 to December 2019 in our institution. To reduce the patient selection bias, propensity score matching (PSM) analysis was used. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and adverse events (AEs) were compared between the two groups. In addition, prognostic factors affecting PFS and OS were analyzed by univariate and multivariate methods. RESULTS: A total of 312 eligible HCC patients were included in the study, including 140 patients in the DEB-TACE group and 172 patients in the cTACE group. 110 patients were chosen in each group after PSM analysis and there were no significant differences in baseline characteristics (P > 0.05). Before PSM analysis, DEB-TACE had better ORR and DCR compared to cTACE group (P < 0.05). After PSM analysis, the ORR for DEB-TACE group was still higher than that for cTACE group, while no significant difference in the DCR between the two groups. In addition, DEB-TACE group had better survival benefits than cTACE group before PSM analysis (mPFS: 11.5 months vs 9.0 months, P < 0.001; mOS: 24.0 months vs 19.2 months, P = 0.045). Similarly, after PSM analysis, the median PFS and OS in the DEB-TACE group were still higher than that in the cTACE group (mPFS: 11.1 months vs 9.0 months, P = 0.015; mOS: 25.0 months vs 19.0 months, P = 0.030). Further, the univariate and multivariate analysis indicated that DEB-TACE treatment was a positive prognostic factor for PFS and OS. CONCLUSION: DEB-TACE with CalliSpheres microspheres might be an effective and safe treatment for patients with unresectable HCC beyond up-to-seven criteria. CI - Copyright (c) 2022 Elsevier Masson SAS. All rights reserved. FAU - Shi, Qin AU - Shi Q AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China; Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. FAU - Liu, Jiacheng AU - Liu J AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China. FAU - Li, Tongqiang AU - Li T AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China. FAU - Zhou, Chen AU - Zhou C AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China. FAU - Wang, Yingliang AU - Wang Y AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China. FAU - Huang, Songjiang AU - Huang S AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China. FAU - Yang, Chongtu AU - Yang C AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China. FAU - Chen, Yang AU - Chen Y AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China. FAU - Xiong, Bin AU - Xiong B AD - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China; Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China. Electronic address: herr_xiong@126.com. LA - eng PT - Journal Article DEP - 20220303 PL - France TA - Clin Res Hepatol Gastroenterol JT - Clinics and research in hepatology and gastroenterology JID - 101553659 SB - IM MH - *Carcinoma, Hepatocellular/pathology MH - *Chemoembolization, Therapeutic/methods MH - Humans MH - *Liver Neoplasms/pathology MH - Propensity Score MH - Retrospective Studies MH - Treatment Outcome OTO - NOTNLM OT - Callispheres drug-eluting beads OT - Hepatocellular carcinoma OT - Propensity score matching OT - Transarterial chemoembolization OT - Up-to-seven criteria COIS- Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/03/06 06:00 MHDA- 2022/06/15 06:00 CRDT- 2022/03/05 20:12 PHST- 2021/10/17 00:00 [received] PHST- 2022/02/04 00:00 [revised] PHST- 2022/02/18 00:00 [accepted] PHST- 2022/03/06 06:00 [pubmed] PHST- 2022/06/15 06:00 [medline] PHST- 2022/03/05 20:12 [entrez] AID - S2210-7401(22)00036-5 [pii] AID - 10.1016/j.clinre.2022.101893 [doi] PST - ppublish SO - Clin Res Hepatol Gastroenterol. 2022 May;46(5):101893. doi: 10.1016/j.clinre.2022.101893. Epub 2022 Mar 3.